HC Wainwright & Co. maintains Crescent Biopharma at Buy, raises price target to $40 from $36

CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights Completed dose escalation in Phase 1/2 ASCEND trial of CR-001 with more than 125 patients dosed across United States, Europe and South Korea; enrolling standard of care chemotherapy com

H.C. Wainwright reiterated a Buy rating and $36.00 price target on Crescent Biopharma (CBIO), citing progress in mid-stage clinical trials for its CR-001 drug. The stock trades at $11.84, with potential upside of over 200%. Crescent announced completion of dose escalation in its ASCEND trial and enrollment of over 125 patients. The company aims to dose over 2,000 patients by mid-2027 and start Phase 3 trials in early 2028.

Stifel maintained a Buy rating and $28.00 price target for Crescent Biopharma (CBIO) after its pipeline update, noting progress in trials and patient dosing. The stock, trading at $12.48, has dropped 16% in a week. Crescent recently raised $143.7M via a public offering, with H.C. Wainwright upgrading its rating to Buy with a $36.00 target. The company's enterprise value is below $500M, and it expects to dose over 2,000 patients by mid-2027.

Crescent Biopharma (CBIO) announced enrollment in CR-001 chemo combination cohorts and IND allowance for CR-002, with initial data expected in 2027. The company completed CR-001 monotherapy dose escalation and expects initial monotherapy data from over 125 patients and ORR in up to 12 1L NSCLC patients by Q1 2027. The FDA allowed IND for CR-002, with a global Phase 1/2 APOLLO trial to start Q4 2026 and initial data anticipated in H2 2027.

CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 15, 2026, Crescent Biopharma, Inc. (“Crescent” or the “Company”) issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plus standard of care

Stifel maintained a Buy rating and $28 target on Crescent Biopharma (NASDAQ:CBIO) after FDA clearance of its CR-002 drug. The stock trades at $13.94, down 28% in six months. Stifel expects trial data in 2027. Crescent raised $143.7M in a public offering. H.C. Wainwright upgraded CBIO to Buy with a $36 target.